Global NGS Sample Preparation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The next-generation sequencing sample preparation market size is expected to grow from USD 2.7 billion in 2025 to USD 3.08 billion in 2026 and is forecast to reach USD 5.95 billion by 2031 at 14.08% CAGR over 2026-2031. This report is Segmented by Product (Reagents & Consumables, Automation Workstations, and More), Workflow Phase (Nucleic-Acid Extraction & Purification, and More), Application (Diagnostics, Drug Discovery, and More), End-User (Hospitals & Reference Labs, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global NGS Sample Preparation Market Trends and Insights

Rising Prevalence of Infectious and Emerging Pathogens

Over half of Sub-Saharan African nations now run in-country NGS surveillance platforms, accelerating pathogen tracking capacity built during the COVID-19 response. Regional consortia, such as the Asia Pathogen Genomics Initiative, aggregate resources to mitigate persistent supply bottlenecks. Validated metagenomic assays reach 93.6% sensitivity for respiratory viruses in under 24 hours. Coupling nanopore sequencing with antimicrobial-resistance calling delivers >90% concordance with phenotypic data, reinforcing sample-prep upgrades designed for diverse specimen matrices. Laboratories, therefore, prioritize kits compatible with low-input, pathogen-rich samples and shortened turnaround.

Falling Sequencing-Per-Base Costs and Open-Platform Chemistry

Component prices for flow cells, enzymes, and terminators continue to decline as multi-vendor supply chains mature, allowing new entrants to commercialize benchtop sequencers for below USD 100,000. Illumina’s on-flow-cell library chemistry, scheduled for commercial release in 2025, removes separate library prep steps and lowers overall per-run costs. Platform-agnostic kits such as CapTrap-seq give laboratories flexibility to switch instruments without revalidating upstream preparation. These developments shift capital budget decisions from hardware replacement cycles to chemistry and workflow optimization, reinforcing price competition across reagents.

Capital-Intensive Automation and Consumable Costs for Mid-Size Laboratories

Units such as the MGISP-960 demand six-figure investments and steady throughput; labs processing under 1,000 samples each month struggle to realize per-sample savings. Consumables can comprise up to 70% of total preparation cost, pressuring mid-volume facilities to outsource sequencing. Ambient-temperature stabilization chemistries from Biomatrica now maintain DNA integrity without a cold chain, offering a partial remedy and trimming logistics spend. Sample-prep-as-a-service providers bridge capability gaps, yet slow direct capital equipment growth.

Other drivers and restraints analyzed in the detailed report include:

• Automation Reducing Hands-On Time in High-Throughput Laboratories
• Clinical Adoption of Rapid On-Board Sample-to-Answer Systems
• Fragmented Regulatory Guidance for Laboratory Developed Tests Across Regions

Segment Analysis

Reagents and consumables held 64.12% of the next-generation sequencing sample preparation market share in 2025, underscoring their recurring revenue profile. Automation workstations, though lower in absolute revenue, are expected to grow 18.28% annually as staffing shortages raise the cost of manual workflows. The NEBNext Ultra II enzymatic fragmentation kit cuts hands-on time to 15 minutes while maintaining high library complexity, exemplifying how chemistry advances complement automation. Within this segment, value-added devices that monitor reagent use and prevent pipetting errors secure premium pricing and pay-back periods of under 18 months for labs exceeding 500 monthly samples.

Laboratories increasingly bundle automation hardware with software dashboards that predict reagent depletion, aligning purchasing with just-in-time delivery. DISPENDIX’s I.DOT handler automates 80% of library prep steps and provides visual QC checkpoints, lowering re-run rates. As throughput rises, these integrated platforms optimize reagent consumption and strengthen vendor lock-in strategies.

Diagnostics, led by oncology, generated 53.62% of 2025 revenue as genomic profiling became the standard of care across major cancer subtypes. NIPT is forecast to log a 17.62% CAGR through 2031, fueled by broader payer coverage and expanding paternal haplotype assays. Precision-oncology panels now detect minimal residual disease in early-stage tumors, guiding adjuvant therapy choices and heightening sensitivity requirements for sample prep. Labcorp’s alliance with Ultima Genomics on whole-genome-based residual-disease testing illustrates how clinical labs refine workflows for ultralow variant allele frequencies.

Drug discovery groups adopt single-cell sequencing to decipher tumor microenvironments, while agricultural researchers deploy targeted genotyping-by-sequencing to improve crop traits, diversifying revenue beyond human health. These varied use cases sustain the next-generation sequencing sample preparation market as kit manufacturers tailor chemistries for circulating DNA, FFPE tissue, or plant material, ensuring workflow adaptability.

Complete Report Scope:

• By Product Class
  • Reagents & Consumables
  • Automation Workstations
  • Other Consumables
• By Workflow Phase
  • Nucleic-acid Extraction & Purification
  • Library Construction
  • Target Enrichment / Amplicon Generation
  • Quality Control & Quantification
• By Application
  • Diagnostics
  • Drug Discovery / Functional Genomics
  • Agriculture & Animal Research
  • Other Research Applications
• By End-User
  • Hospitals & Reference Labs
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.10% of 2025 revenue, anchored by robust healthcare reimbursement structures and clear regulatory pathways that reduce adoption risk. Illumina, Thermo Fisher Scientific, and Element Biosciences maintain regional manufacturing and support footprints, easing customer validation cycles. Canada’s community-hospital liquid-biopsy programs illustrate clinical uptake, while Mexico leverages proximity to U.S. suppliers to scale reference-lab capacity.

Europe benefits from coordinated research funding and infrastructural maturity across Germany, the United Kingdom, France, Italy, and Spain. Harmonized IVDR rules enable cross-border kit deployment, although additional documentation imposes cost overheads that smaller labs offset via consortium purchasing models. Emerging Eastern European markets gain technology transfer through joint projects with established genomic centers, broadening regional contribution to the next-generation sequencing sample preparation market size.

Asia Pacific is the fastest-growing region at a 14.22% CAGR as governments embed genomics in public-health agendas. India’s IndiGen initiative, which sequenced 1,000 genomes, jump-started local bio-banking capacity. China’s MGI Tech scales automated workstations domestically and exports to Southeast Asia, while Japan pioneers rapid sequencing in tertiary hospitals. Nonetheless, cold-chain logistics and varied regulatory standards remain hurdles that vendors address via ambient-temperature stabilizers and local compliance support offices.

List of Companies Covered in this Report:

• Illumina
• Thermo Fisher Scientific
• QIAGEN
• Agilent Technologies
• Roche
• PerkinElmer
• Danaher Corp (Beckman Coulter)
• BGI
• Eurofins
• Bio-Rad Laboratories
• Oxford Nanopore Technologies
• Pacific Biosciences
• Macrogen
• Integrated DNA Technologies
• Genomatix
• Tecan Group
• Hamilton Company
• New England Biolabs
• Swift Biosciences
• Helix OpCo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support